BIOGEN INC. - COMMON STOCK

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

15 May 2023 19:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

05 May 2023 14:32:54 By NetDania Notify

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

03 May 2023 09:45:11 By NetDania Notify

NetDania - New 12 months High: BIOGEN INC. - COMMON STOCK

01 May 2023 14:12:43 By NetDania Notify

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

25 Apr 2023 15:04:23 By Nasdaq GlobeNewswire

Biogen Appoints Adam Keeney as Head of Corporate Development

04 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

30 Mar 2023 19:30:00 By Nasdaq GlobeNewswire

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

30 Mar 2023 19:30:00 By Nasdaq GlobeNewswire

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

29 Mar 2023 08:45:00 By Nasdaq GlobeNewswire

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

22 Mar 2023 20:32:40 By Nasdaq GlobeNewswire

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

16 Mar 2023 06:30:14 By Nasdaq GlobeNewswire

Biogen Appoints Chuck Triano as Head of Investor Relations

14 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

08 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

05 Mar 2023 18:30:00 By Nasdaq GlobeNewswire

Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration

27 Feb 2023 18:30:00 By Nasdaq GlobeNewswire

Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

06 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Lecanemab Receives Priority Review Status in Japan

29 Jan 2023 18:30:00 By Nasdaq GlobeNewswire

Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

26 Jan 2023 18:30:00 By Nasdaq GlobeNewswire

Biogen Names Priya Singhal as Executive Vice President, Head of Development

05 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

04 Jan 2023 07:30:00 By Nasdaq GlobeNewswire